Theos Tsakiridis

Theos Tsakiridis


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
EAElham Ahmadi
Elham Ahmadi
SWSimon Wang
Simon Wang
MGMohammad Gouran-Savadkoohi
Mohammad Gouran-Savadkoohi
GDGeorgia Douvi
Georgia Douvi
NINaghmeh Isfahanian
Naghmeh Isfahanian
TTTheos Tsakiridis
Theos Tsakiridis
Metabolic dysregulation is an early event in carcinogenesis. Here, we examined the expression of enzymes involved in de novo lipogenesis (ATP-citrate lyase: ACLY), glucose uptake (Glucose Transporter 1: GLUT1), and folate–glutamate metabolism (Prostate-Specific Membrane Antigen: PSMA) as potential biomarkers of risk for early prostate cancer progression. Patients who were managed initially on active surveillance with a Gleason score of 6 or a low-volume Gleason score of 7 (3 + 4) were accrued from a prostate cancer diagnostic assessment program. Patients were asked to donate their baseline diagnostic biopsy tissues and permit access to their clinical data. PSMA, GLUT1, and ACLY expression were examined with immunohistochemistry (IHC) in baseline biopsies, quantitated by Histologic Score for expression in benign and malignant glands, and compared with patient time remaining on active surveillance (time-on-AS). All three markers showed trends for elevated expression in malignant compared to benign glands, which was statistically significant for ACLY. On univariate analysis, increased PSMA and GLUT1 expression in malignant glands was associated with shorter time-on-AS (HR: 5.06, [CI 95%: 1.83–13.94] and HR: 2.44, [CI 95%: 1.10–5.44], respectively). Malignant ACLY and benign gland PSMA and GLUT1 expression showed non-significant trends for such association. On multivariate analysis, overexpression of PSMA in malignant glands was an independent predictor of early PC progression (p = 0.006). This work suggests that the expression of metabolic enzymes determined by IHC on baseline diagnostic prostate biopsies may have value as biomarkers of risk for rapid PC progression. PSMA may be an independent predictor of risk for progression and should be investigated further in systematic studies.

27 April 2025 in The Prostate
Verified
Journal Article
Open access
AGAndre Gouveia
Andre Gouveia
AMAruz Mesci
Aruz Mesci
NINaghmeh Isfahanian
Naghmeh Isfahanian
IDIan Dayes
Ian Dayes
KQKimmen Quan
Kimmen Quan
TTTheos Tsakiridis
Theos Tsakiridis
Background: Standard treatment for unfavorable‐intermediate and high‐risk prostate cancer involves androgen deprivation therapy (ADT) in combination with pelvic conventional fractionation (CF) external beam radiotherapy (EBRT) and a CF‐EBRT or brachytherapy boost to the prostate. This trial compared CF‐EBRT boost with stereotactic body radiotherapy (SBRT) boost after pelvic CF‐EBRT.Methods: Patients were randomized to receive a boost using either CF‐EBRT (32–34 Gy in 15–17 fractions) or SBRT (19.5–21 Gy in three weekly fractions) following pelvic CF‐EBRT (45–46 Gy in 23–25 fractions). The primary objective was to assess early (3‐month post‐radiotherapy) gastrointestinal (GI) and genitourinary (GU) quality of life (QoL), using the expanded prostate index composite (EPIC) score. Secondary objectives included long‐term QoL, International Prostate Symptom Score (IPSS) changes, toxicity assessments, and long‐term disease control outcomes. Linear regression and Fisher's exact test were used for analysis.Results: Of the 100 patients randomized, 53 received CF‐EBRT, and 47 received SBRT. After a mean follow‐up of 18.5 months, no significant differences were observed in EPIC score changes between CF‐EBRT and SBRT at 3 months posttreatment for urinary (11.5 vs. 8.6, p = 0.23), bowel (5.2 vs. 6.4, p = 0.57), and overall QoL (8.3 vs. 7.5, p = 0.61). IPSS scores were similar (p = 0.11), and CTCAE v.5.0 toxicity rates were comparable, with an odds ratio of 0.90 (p > 0.99). Biochemical failure rates were under 5% for both groups.Conclusions: This is the first randomized trial to report QoL outcomes after SBRT boost radiotherapy in patients with unfavorable‐intermediate and high‐risk prostate cancer. SBRT boost after pelvic CF‐EBRT is well‐tolerated and demonstrates comparable outcomes in QoL and toxicity to the CF‐EBRT boost. Further follow‐up is needed to assess the long‐term effects on QoL, toxicity, and disease control.Trial Registration: ClinicalTrials.gov identifier: NCT03380806.